The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.

The goal of the DDRCC Biorepository is to collect human samples and health information to store for future research. Samples to be collected are blood, tissue (gastrointestinal, liver, pancreas and/or lymph nodes), stool, and cheek swabs. Participants may be eligible to enroll if scheduled for a clinical visit or surgical procedure during which these samples could be collected.

This study is designed to explore a new treatment option for motor symptoms in people with Parkinson's disease. Motor symptoms and gait disturbance for Parkinson's are often disabling and can increase risk of falls and requce quality of life. We are testing whether a non-invasive brain stimulation technique called transcutaneous auricular vagus nerve stimulation (taVNS) is tolerable, acceptable and can be administered at-home and used to improve symptoms of Parkinson's disease. TaVNS delivers electrical impulses through the skin of the ear to the vagus nerve which research has shown modulates brain activity. The purpose of this research is to see whether this treatment approach is feasible, tolerable and and potentially effective at treating the symptoms of Parkinson's disease. If successful, this research study will hopefully lead to a larger study in the future where the efficacy of the treatments can be studied.

Study 812P310 is a multicenter, open-label extension study aimed to assess long-term safety and efficacy of SPN-812 in the treatment of ADHD in pediatric subjects who have participated in a previous blinded study of SPN-812.

All subjects who complete a blinded study of SPN-812 will have the option to participate in the OLE study in which all subjects receive SPN-812 (Study Medication, SM). Starting dose, dose range, and dose adjustments are all based on which double blind study the subject completed and, if applicable, the current age of the subject (Table 1). A subject who completed Study 812P202, 812P301 or 812P303, enters this OLE study at age 11 years, and then turns 12 while still in the study, their upper potential dose limit will then be raised from 400 mg to 600 mg and titration may occur at either 100 or 200 mg/week, as specified for the 12-17 year-old age group.

In the current study, we will recruit individuals using addictive drugs (cocaine, cannabis, opioids, or methamphetamine) and non-drug use control individuals. The study participants will fill out questionnaires, consent, and donate samples (urine, saliva, nasal swab, and blood). These samples will be used to study the causes of unhealthy conditions during drug uses. Our goal is to prevent or treat the drug-associated unhealthy conditions (i.e., anxiety, memory impairment).

The purpose of this study is to evaluate investigational treatments (study drug) for locally advanced/metastatic colorectal cancer. This study seeks to see if Fruquintinib in combination with TAS-102 improves overall survival when compared to Fruquintinib alone.The goal is to determine the optimal dose level, safety, and tolerability for the study drug.Treatment for this study may be up to 3 years. The procedures include blood and urine samples, questionnaires, infusions, and CT scans. Risks include high blood pressure, diarrhea, vomiting, reduced appetite, weight loss, hoarse voice, joint pain, and weakness. You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

The overall objective of this proposal is to identify patients with Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) that are at the highest risk for progressive disease at the time of diagnosis. Our central hypothesis is that novel quantitative imaging and specific blood markers will be associated with progressive RA-ILD. Approximately 80 subjects will be enrolled from MUSC and participation with last up to 2 years.

This study examines how parents and adolescents communicate about alcohol and marijuana during mid-to-late adolescence, a period marked by rising substance use risk. Although many parents want to reduce harm, they often receive unclear guidance, and what parents intend to convey may not align with what adolescents perceive. Building on prior work showing that alcohol-specific communication is multidimensional and meaningfully linked to youth drinking outcomes, this study surveys parent–adolescent dyads (ages 15–18) to assess the content, frequency, and perception of substance-related conversations. The study also extends prior research by directly comparing parent and youth reports to identify alignment and discrepancies in communication. In addition, it addresses a major gap by characterizing marijuana-specific parental communication, which remains understudied despite increasing adolescent use. Finally, the study tests whether parents' trauma histories, particularly trauma involving substance use, shape how and what parents communicate to their children about alcohol and marijuana.

This study aims to better understand the experiences and perspectives of people with opioid use disorder (OUD) who have recently been hospitalized for a medical condition. Participants will complete a brief, confidential survey about their views on medications for opioid use disorder (MOUD), including barriers to starting treatment, factors that support treatment decisions, and what information they find most helpful. Individuals who meet eligibility criteria will be invited to participate. The information collected will help identify what patients need and prefer when making decisions about MOUD during a hospital stay. Findings from this study will guide the design of a future intervention that reflects patient identified needs and priorities.

LiveWell mBC is a group-based skills training program for women with metastatic breast cancer (mBC). The program teaches skills from dialectical behavioral therapy, an evidence-based psychotherapy, that have been adapted specifically to help women live as well as possible, with metastatic breast cancer. LiveWell mBC involves meeting with a small group of women with mBC plus two skills trainers 9 times total via telemedicine. Meetings include orientation plus 8 sessions learning and practicing skills including mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness and they last 90 minutes each. We are interested in seeing whether the program can help women to balance their emotions and better manage distress (e.g., anxiety, sadness) and symptoms (e.g., fatigue, breathlessness, pain) that can be common when living with mBC.

Participants will be randomly assigned to one of two groups. They will have a 2 in 3 chance of being assigned to LiveWell mBC (experimental group) and a 1 in 3 chance of being assigned to Usual Care (control group). Women in the usual care group will continue to receive their standard oncology care. Participants in both groups will complete questionnaires four times total. Participants may be invited to participate in an exit interview about their experience. Participants will be compensated for completing questionnaires and the interview. For most people, participation will last approximately 4 months.